{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:56:30Z","timestamp":1781632590234,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with advanced or metastatic breast cancer (mBC), adherence to treatment, supportive therapy, and comorbidity medication is important for prolonging survival time, reducing symptom burden and side effects, and improving quality of life. The aim of the present study was to determine medication adherence and potential influencing factors in patients with advanced or mBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with advanced or mBC treated at the University Hospital W\u00fcrzburg living in Bavaria, were included in the BRE-BY-MED \u201cBreast Cancer Care in Bavaria for Patients with Metastatic Disease\u201d cohort study (DRKS00026601). Self-reported adherence was analysed using data from patients at baseline, and after 3-, 6-, and 12-months of follow-up, and using Bavarian cancer registry data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between July 2022 and February 2024, 93 patients (median age 57 years; IQR\u2009=\u200948\u201364), were consecutively enrolled in the BRE-BY-MED study. At baseline, 75.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970) and 86.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200980) of the patients reported being adherent and dosage adherent, respectively. During the follow-up period, no relevant changes in adherence levels were observed. Supportive therapy and medication for comorbidities were most affected by non-adherence. The most common reasons for non-adherence were medication beliefs, forgetfulness, and side effects. For 81.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200969) of the patients, complementary cancer registry data were available and complete, and therapy persistence was found in 78.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954) of these patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The observed adherence rates indicate that tailored interventions to improve adherence to supportive therapy and medication for comorbidities in patients with advanced or mBC are needed, particularly considering the reasons for non-adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15641-y","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:55:50Z","timestamp":1769759750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study"],"prefix":"10.1186","volume":"26","author":[{"given":"Lilly Sophia","family":"Brandstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"M\u00fcller-Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"M\u00fcller-Nordhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Peter","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"7","key":"15641_CR1","first-page":"386","volume":"7","author":"M daCosta DiBonaventura","year":"2014","unstructured":"daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386\u201396.","journal-title":"Am Health Drug Benefits"},{"issue":"Suppl 7","key":"15641_CR2","doi-asserted-by":"publisher","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","volume":"23","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11-19.","journal-title":"Ann Oncol"},{"issue":"3","key":"15641_CR3","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.05.01","volume":"7","author":"M Hattori","year":"2018","unstructured":"Hattori M, Iwata H. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable? Chin Clin Oncol. 2018;7(3):23.","journal-title":"Chin Clin Oncol"},{"issue":"11","key":"15641_CR4","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.21037\/gs-23-258","volume":"12","author":"M Luo","year":"2023","unstructured":"Luo M, Lin X, Hao D, Shen KW, Wu W, Wang L, et al. Incidence and risk factors of lymph node metastasis in breast cancer patients without preoperative chemoradiotherapy and neoadjuvant therapy: analysis of SEER data. Gland Surg. 2023;12(11):1508\u201324.","journal-title":"Gland Surg"},{"key":"15641_CR5","unstructured":"Leitlinienprogramm Onkologie: S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. In., vol. Version 4.3: Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 2020."},{"issue":"3","key":"15641_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>3.0.CO;2-1","volume":"88","author":"KS Ogle","year":"2000","unstructured":"Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88(3):653\u201363.","journal-title":"Cancer"},{"key":"15641_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0057-2","volume":"2","author":"D Drzayich Antol","year":"2018","unstructured":"Drzayich Antol D, Waldman Casebeer A, Khoury R, Michael T, Renda A, Hopson S, et al. The relationship between comorbidity medication adherence and health related quality of life among patients with cancer. J Patient Rep Outcomes. 2018;2:29.","journal-title":"J Patient Rep Outcomes"},{"key":"15641_CR8","volume-title":"Adherence to long-term therapies : evidence for action","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Adherence to long-term therapies\u202f: evidence for action. Geneva: World Health Organization; 2003."},{"issue":"Suppl 1","key":"15641_CR9","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0895-4356(01)00457-7","volume":"54","author":"J Dunbar-Jacob","year":"2001","unstructured":"Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54(Suppl 1):S57-60.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"15641_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jac\/dki066","volume":"55","author":"B Vrijens","year":"2005","unstructured":"Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005;55(5):616\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"15641_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","volume":"2015","author":"WY Lam","year":"2015","unstructured":"Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015;2015:217047.","journal-title":"BioMed Res Int"},{"issue":"2","key":"15641_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/mpr-1201","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117\u201322.","journal-title":"Med Pharm Rep"},{"issue":"1","key":"15641_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0193945914524492","volume":"37","author":"LG Park","year":"2015","unstructured":"Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2015;37(1):28\u201349.","journal-title":"West J Nurs Res"},{"issue":"2","key":"15641_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"15641_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11096-013-9833-5","volume":"36","author":"LR Ayres","year":"2014","unstructured":"Ayres LR, Baldoni Ade O, Borges AP, Pereira LR. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm. 2014;36(1):45\u201354.","journal-title":"Int J Clin Pharm"},{"key":"15641_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.05.013","author":"C Cahir","year":"2015","unstructured":"Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K. Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: a systematic review and meta-analysis. Patient Educ Couns. 2015. https:\/\/doi.org\/10.1016\/j.pec.2015.05.013.","journal-title":"Patient Educ Couns"},{"issue":"1\u20132","key":"15641_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000100444","volume":"71","author":"RT Chlebowski","year":"2006","unstructured":"Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1\u20132):1\u20139.","journal-title":"Oncology"},{"issue":"4","key":"15641_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/1940-6207.CAPR-13-0389","volume":"7","author":"RT Chlebowski","year":"2014","unstructured":"Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res. 2014;7(4):378\u201387.","journal-title":"Cancer Prev Res"},{"issue":"3","key":"15641_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-017-4561-5","volume":"167","author":"LK Lambert","year":"2018","unstructured":"Lambert LK, Balneaves LG, Howard AF, Gotay CC. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;167(3):615\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"15641_CR20","first-page":"56","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56\u201366.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"15641_CR21","first-page":"5075","volume":"28","author":"O AlOmeir","year":"2020","unstructured":"AlOmeir O, Patel N, Donyai P. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Support Care Cancer. 2020;28(11):5075\u201384.","journal-title":"Support Care Cancer"},{"issue":"2","key":"15641_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-017-4317-2","volume":"165","author":"C Lin","year":"2017","unstructured":"Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat. 2017;165(2):247\u201360.","journal-title":"Breast Cancer Res Treat"},{"key":"15641_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/PPA.S126651","volume":"11","author":"Z Moon","year":"2017","unstructured":"Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305\u201322.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"15641_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-018-05073-z","volume":"174","author":"R Paranjpe","year":"2019","unstructured":"Paranjpe R, John G, Trivedi M, Abughosh S. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019;174(2):297\u2013305.","journal-title":"Breast Cancer Res Treat"},{"key":"15641_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.breast.2021.05.005","volume":"58","author":"N Peddie","year":"2021","unstructured":"Peddie N, Agnew S, Crawford M, Dixon D, MacPherson I, Fleming L. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast. 2021;58:147\u201359.","journal-title":"Breast"},{"issue":"Suppl 3","key":"15641_CR26","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2105\/AJPH.2014.302490","volume":"105","author":"MC Roberts","year":"2015","unstructured":"Roberts MC, Wheeler SB, Reeder-Hayes K. Racial\/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health. 2015;105(Suppl 3):e4\u201315.","journal-title":"Am J Public Health"},{"key":"15641_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010107","author":"KI Toivonen","year":"2020","unstructured":"Toivonen KI, Williamson TM, Carlson LE, Walker LM, Campbell TS. Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers13010107.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"15641_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11764-014-0374-2","volume":"8","author":"JR Van Liew","year":"2014","unstructured":"Van Liew JR, Christensen AJ, de Moor JS. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv. 2014;8(3):521\u201331.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"15641_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jan.14253","volume":"76","author":"H Xu","year":"2020","unstructured":"Xu H, Zhang XJ, Wang DQ, Xu L, Wang AP. Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: a qualitative systematic review. J Adv Nurs. 2020;76(2):445\u201358.","journal-title":"J Adv Nurs"},{"issue":"6","key":"15641_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ctrv.2012.12.014","volume":"39","author":"M Verbrugghe","year":"2013","unstructured":"Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39(6):610\u201321.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"15641_CR31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/annonc\/mdt433","volume":"25","author":"MTE Puts","year":"2014","unstructured":"Puts MTE, Tu HA, Tourangeau A, Howell D, Fitch M, Springall E, et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol. 2014;25(3):564\u201377.","journal-title":"Ann Oncol"},{"issue":"6","key":"15641_CR32","doi-asserted-by":"publisher","first-page":"E192","DOI":"10.1188\/12.CJON.E192-E197","volume":"16","author":"J Lester","year":"2012","unstructured":"Lester J. Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. Clin J Oncol Nurs. 2012;16(6):E192-197.","journal-title":"Clin J Oncol Nurs"},{"issue":"83","key":"15641_CR33","first-page":"231","volume":"15","author":"DM Geynisman","year":"2013","unstructured":"Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;15(83):231\u201341.","journal-title":"Discov Med"},{"key":"15641_CR34","doi-asserted-by":"crossref","unstructured":"Muluneh B, Alexander M, Deal AM, Deal M, Markey J, Neal J, Bernard SA, Valgus J, Dressler LG. Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. J Clin Oncol. 2012; 30(15_suppl):6042\u20136042.","DOI":"10.1200\/jco.2012.30.15_suppl.6042"},{"key":"15641_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-397","volume":"14","author":"C Brito","year":"2014","unstructured":"Brito C, Portela MC, de Vasconcellos MT. Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014;14:397.","journal-title":"BMC Cancer"},{"key":"15641_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12339","author":"M Verbrugghe","year":"2017","unstructured":"Verbrugghe M, Verhaeghe S, Decoene E, De Baere S, Vandendorpe B, Van Hecke A. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care. 2017. https:\/\/doi.org\/10.1111\/ecc.12339.","journal-title":"Eur J Cancer Care"},{"issue":"11","key":"15641_CR37","first-page":"3115","volume":"23","author":"C Cahir","year":"2015","unstructured":"Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women\u2019s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer. 2015;23(11):3115\u201330.","journal-title":"Support Care Cancer"},{"issue":"3","key":"15641_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1590\/S0004-28032014000300004","volume":"51","author":"AG Figueiredo Junior","year":"2014","unstructured":"Figueiredo Junior AG, Forones NM. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer. Arq Gastroenterol. 2014;51(3):186\u201391.","journal-title":"Arq Gastroenterol"},{"key":"15641_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-1851-z","volume":"5","author":"S Feiten","year":"2016","unstructured":"Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, K\u00f6ppler H, et al. Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice. Springerplus. 2016;5:270.","journal-title":"Springerplus"},{"key":"15641_CR40","unstructured":"BRE-BY-MED \/ digiOnko.\u00a0https:\/\/www.med.uni-wuerzburg.de\/en\/epidemiologie\/forschung\/projekte\/versorgungsforschung\/bre-by-med-digionko\/. Accessed 27 Jan 2026."},{"issue":"2","key":"15641_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/2396987320910596","volume":"6","author":"FA Eichner","year":"2021","unstructured":"Eichner FA, Schwarzbach CJ, Keller M, Haeusler KG, Hamann GF, Sander D, et al. Trial design and pilot phase results of a cluster-randomised intervention trial to improve stroke care after hospital discharge - The structured ambulatory post-stroke care program (SANO). Eur Stroke J. 2021;6(2):213\u201321.","journal-title":"Eur Stroke J"},{"key":"15641_CR42","unstructured":"[Bundesministerium f\u00fcr Gesundheit] German Federal Ministry of Health. [Krebsregister] Cancer registry.\u00a0https:\/\/www.bundesgesundheitsministerium.de\/service\/begriffe-von-a-z\/k\/krebsregister.\u00a0Accessed 27 Jan 2026."},{"issue":"5","key":"15641_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"15641_CR44","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"P Fayers","year":"2001","unstructured":"Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 Scoring Manual. 3rd Edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001.","edition":"3rd Edition"},{"issue":"1\u20132","key":"15641_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2009.06.019","volume":"122","author":"B L\u00f6we","year":"2010","unstructured":"L\u00f6we B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the patient health questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122(1\u20132):86\u201395.","journal-title":"J Affect Disord"},{"issue":"5 Suppl 1","key":"15641_CR46","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","volume":"45","author":"D Cella","year":"2007","unstructured":"Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;45(5 Suppl 1):S3-s11.","journal-title":"Med Care"},{"issue":"1","key":"15641_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0269215517714297","volume":"32","author":"G Liegl","year":"2018","unstructured":"Liegl G, Rose M, Correia H, Fischer HF, Kanlidere S, Mierke A, et al. An initial psychometric evaluation of the German PROMIS v1.2 physical function item bank in patients with a wide range of health conditions. Clin Rehabil. 2018;32(1):84\u201393.","journal-title":"Clin Rehabil"},{"issue":"1","key":"15641_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12885-025-13548-8","volume":"25","author":"LS Brandstetter","year":"2025","unstructured":"Brandstetter LS, Grau A, Heuschmann PU, M\u00fcller-Reiter M, Salmen J, St\u00f6rk S, et al. Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study. BMC Cancer. 2025;25(1):125.","journal-title":"BMC Cancer"},{"issue":"01","key":"15641_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-2007-970791","volume":"58","author":"M Neumann","year":"2008","unstructured":"Neumann M, Wirtz M, Bollschweiler E, Warm M, Wolf J, Pfaff H. Psychometrische Evaluation der deutschen Version des Messinstruments \u201eConsultation and Relational Empathy\u201d (CARE) am Beispiel von Krebspatienten. Psychother Psychosom Med Psychol. 2008;58(01):5\u201315.","journal-title":"Psychother Psychosom Med Psychol"},{"key":"15641_CR50","unstructured":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut. Krebs in Deutschland f\u00fcr 2019\/2020. In., vol. 14. Ausgabe. Berlin; 2023."},{"key":"15641_CR51","unstructured":"National Cancer Institute. Cancer statistics: fact sheets, cancer of the breast incidence and moortality, SEER incidence. Surveillance Epidemiology and End Results. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html#incidence-mortality.\u00a0Accessed 27 Jan 2026."},{"key":"15641_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.breast.2020.04.009","volume":"52","author":"S Frank","year":"2020","unstructured":"Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, et al. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast. 2020;52:50\u20137.","journal-title":"Breast"},{"issue":"11","key":"15641_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293830","volume":"18","author":"X Gao","year":"2023","unstructured":"Gao X, Zhang F, Zhou Q, Xu H, Bian J. Metastasis, characteristic, and treatment of breast cancer in young women and older women: a study from the surveillance, epidemiology, and end results registration database. PLoS One. 2023;18(11):e0293830.","journal-title":"PLoS One"},{"issue":"5","key":"15641_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/phar.1399","volume":"34","author":"DA McCue","year":"2014","unstructured":"McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34(5):481\u201394.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"15641_CR55","first-page":"651","volume":"18","author":"J Cashman","year":"2010","unstructured":"Cashman J, Wright J, Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18(5):651\u20135.","journal-title":"Support Care Cancer"},{"key":"15641_CR56","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2147\/PPA.S401480","volume":"17","author":"NM Engel-Nitz","year":"2023","unstructured":"Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X. Palbociclib adherence and persistence in patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-) metastatic breast cancer. Patient Prefer Adherence. 2023;17:1049\u201362.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"15641_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5806-y","volume":"19","author":"M Wallwiener","year":"2019","unstructured":"Wallwiener M, Nabieva N, Feisst M, Fehm T, de Waal J, Rezai M, et al. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer. 2019;19(1):611.","journal-title":"BMC Cancer"},{"issue":"18_suppl","key":"15641_CR58","doi-asserted-by":"publisher","first-page":"18623","DOI":"10.1200\/jco.2006.24.18_suppl.18623","volume":"24","author":"S Mangiapane","year":"2006","unstructured":"Mangiapane S, Hoer A, Gothe H, Barghout V, Haeussler B. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol. 2006;24(18_suppl):18623\u201318623.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15641_CR59","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00432-013-1427-z","volume":"139","author":"P Hadji","year":"2013","unstructured":"Hadji P, Ziller V, Kyvernitakis J, Schmidt N, Kostev K. Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis. J Cancer Res Clin Oncol. 2013;139(7):1149\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"15641_CR60","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.30547","volume":"123","author":"CR Friese","year":"2017","unstructured":"Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123(11):1925\u201334.","journal-title":"Cancer"},{"issue":"3","key":"15641_CR61","doi-asserted-by":"publisher","first-page":"725","DOI":"10.31557\/apjcb.2025.10.3.725-733","volume":"10","author":"L Sayani","year":"2025","unstructured":"Sayani L. Understanding chemotherapy adherence in breast cancer patients: a multidimensional review through the WHO adherence framework. Asian Pac J Cancer Biol. 2025;10(3):725\u201333.","journal-title":"Asian Pac J Cancer Biol"},{"key":"15641_CR62","unstructured":"American Cancer Society. Hormone therapy for breast cancer.\u00a0https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment\/hormone-therapy-for-breast-cancer.html.\u00a0Accessed 27 Jan 2026."},{"key":"15641_CR63","unstructured":"Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2023. https:\/\/www.uptodate.com\/contents\/clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-cancer.\u00a0Accessed 27 Jan 2026."},{"issue":"2","key":"15641_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","volume":"68","author":"EA Rakha","year":"2015","unstructured":"Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68(2):93\u20139.","journal-title":"J Clin Pathol"},{"issue":"20","key":"15641_CR65","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15641_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clbc.2012.11.001","volume":"13","author":"AT Berman","year":"2013","unstructured":"Berman AT, Thukral AD, Hwang W-T, Solin LJ, Vapiwala N. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13(2):88\u201394.","journal-title":"Clin Breast Cancer"},{"key":"15641_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2458-11-249","volume":"11","author":"CL Booker","year":"2011","unstructured":"Booker CL, Harding S, Benzeval M. A systematic review of the effect of retention methods in population-based cohort studies. BMC Public Health. 2011;11:249.","journal-title":"BMC Public Health"},{"issue":"1","key":"15641_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01514-y","volume":"22","author":"F Jansen","year":"2022","unstructured":"Jansen F, Brakenhoff RH, de Baatenburg Jong RJ, Langendijk JA, Leemans CR, Takes RP, et al. Study retention and attrition in a longitudinal cohort study including patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 262 informal caregivers. BMC Med Res Methodol. 2022;22(1):27.","journal-title":"BMC Med Res Methodol"},{"key":"15641_CR69","doi-asserted-by":"publisher","DOI":"10.2196\/68826","volume":"8","author":"LD Braun","year":"2025","unstructured":"Braun LD, Allen HR, Keller JN. Risk factors for community-dwelling older adults dropping out of self-guided, remote, and web-based longitudinal research: predictive modeling of data from the Web-LABrainS platform. JMIR Aging. 2025;8:e68826.","journal-title":"JMIR Aging"},{"key":"15641_CR70","unstructured":"digiOnko [https:\/\/www.digionko-bayern.de\/]"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15641-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:23:45Z","timestamp":1781630625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15641-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15641"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15641-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the principles of the \u201cDeclaration of Helsinki\u201d (as amended in Tokyo, Venice and Hong Kong). The study was approved by the ethics committee of the Medical Faculty of the University Wuerzburg on 29 July 2021 (reference number 137\/21). Written informed consent was obtained from all participants. The responsible data protection officer accepted the data management concept. For the cancer registry data, a data usage agreement was concluded with the Bavarian Cancer Registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}